Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Cardiomyopathies, Primary

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Cardiomyopathies, Primary in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Flögel, U; Hohlfeld, T; Jacoby, C; Krügel, U; Meyer-Kirchrath, J; Oros-Peusquens, AM; Pissarek, M; Schramm, N; Vollmar, S1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Cardiomyopathies, Primary

ArticleYear
Targeting murine heart and brain: visualisation conditions for multi-pinhole SPECT with (99m)Tc- and (123)I-labelled probes.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:9

    Topics: Animals; Benzamides; Brain; Cardiomyopathies; Heart; Humans; Iodine Radioisotopes; Iodobenzenes; Mice; Mice, Transgenic; Myocardium; Oximes; Pyrrolidines; Radiopharmaceuticals; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Swine; Technetium; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon

2009